NKTR logo

Nektar Therapeutics (NKTR)

$74.96

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on NKTR

Market cap

$2.56B

EPS

-6.23

P/E ratio

--

Price to sales

46.09

Dividend yield

--

Beta

1.147797

Price on NKTR

Previous close

$73.69

Today's open

$74.98

Day's range

$74.06 - $76.79

52 week range

$26.45 - $109

Profile about NKTR

CEO

Howard W. Robin

Employees

61

Headquarters

San Francisco, CA

Exchange

NASDAQ Capital Market

Shares outstanding

34142994

Issue type

Common Stock

NKTR industries and sectors

Healthcare

Biotechnology & Life Sciences

News on NKTR

Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

REZOLVE-AD study met all primary and key secondary endpoints, including EASI-75, EASI-90, Itch NRS, vIGA-AD and BSA, on rezpegaldesleukin 24 µg/kg q2w First large, placebo-controlled trial to support T-reg modulation as a clinical mechanism for immunoregulation of chronic inflammatory disease Findings support the continued development of rezpegaldesleukin in the ongoing Phase 3 ZENITH AD clinical program SAN FRANCISCO, Aug. 25, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of peer-reviewed data from the 16-week induction period of REZOLVE-AD, a global, randomized, double-blind, placebo-controlled Phase 2b study evaluating rezpegaldesleukin in adults with moderate-to-severe atopic dermatitis (AD). The publication in The Lancet, a world-leading medical journal, provides the medical and scientific community with the full reporting of efficacy, safety, pharmacodynamics, pharmacokinetics, and biomarker findings from the 16-week induction period of the Phase 2b trial.

news source

PRNewsWire • Aug 25, 2026

news preview

Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in Focus

NKTR's Q2 earnings beat estimates, but revenues fall short. Investor focus stays on rezpeg as late-stage studies advance in autoimmune diseases.

news source

Zacks Investment Research • Aug 14, 2026

news preview

Nektar: Maintaining 'Strong Buy' Rating Due To REZPEG Catalyst, Another Coming

Nektar Therapeutics maintains a Strong Buy rating, driven by REZPEG's late-stage development in atopic dermatitis [AD] and alopecia areata [AA]. The Phase 3 ZENITH AD program is underway, with three pivotal studies targeting moderate-to-severe AD subpopulations; topline data is expected mid-2028. REZPEG's differentiated mechanism aims for long-term disease control and safety advantages over current AD therapies, addressing a $37.3B global market.

news source

Seeking Alpha • Aug 14, 2026

news preview

Nektar Therapeutics Q2 Earnings Call Highlights

Nektar Therapeutics NASDAQ: NKTR said it initiated its global Phase III ZENITH AD program for rezpegaldesleukin, or REZPEG, in moderate-to-severe atopic dermatitis during July, while also finalizing plans for a registrational Phase III trial in alopecia areata following an end-of-Phase II meeting with the U.S. Food and Drug Administration.

news source

MarketBeat • Aug 14, 2026

news preview

Nektar Therapeutics (NKTR) Q2 2026 Earnings Call Transcript

Nektar Therapeutics (NKTR) Q2 2026 Earnings Call Transcript

news source

Seeking Alpha • Aug 14, 2026

news preview

Nektar Therapeutics Announces Second Quarter 2026 Financial Results

SAN FRANCISCO, Aug. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today reported financial results for the second quarter ended June 30, 2026. Cash and investments in marketable securities on June 30, 2026, were $1,023.4 million as compared to $245.8 million on December 31, 2025.

news source

PRNewsWire • Aug 13, 2026

news preview

Nektar Therapeutics (NKTR) Reports Q2 Loss, Misses Revenue Estimates

Nektar Therapeutics (NKTR) came out with a quarterly loss of $1.23 per share versus the Zacks Consensus Estimate of a loss of $2.06. This compares to a loss of $2.78 per share a year ago.

news source

Zacks Investment Research • Aug 13, 2026

news preview

Kuehn Law Encourages Investors of Nektar Therapeutics to Contact Law Firm

NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nektar Therapeutics (NASDAQ: NKTR)  breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, Nektar Therapeutics misrepresented or failed to disclose that: (1) enrollment in its REZOLVE-AA trial for its lead product candidate had not followed applicable instructions and protocol standards; (2) the foregoing was likely to have a significant negative impact on the REZOLVE-AA trial's results; (3) accordingly, the REZOLVE-AA trial's overall integrity and prospects were overstated; and (4) as a result, the Company's public statements were materially false and misleading at all relevant times.

news source

PRNewsWire • Aug 11, 2026

news preview

Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets

SAN FRANCISCO, July 28, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2026 on Thursday, August 13, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m.

news source

PRNewsWire • Jul 28, 2026

news preview

Does Nektar (NKTR) Have the Potential to Rally 104.06% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 104.1% in Nektar (NKTR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

news source

Zacks Investment Research • Jul 28, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Nektar Therapeutics

Open an M1 investment account to buy and sell Nektar Therapeutics commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in NKTR on M1